Atlas Trials

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer

Clinical trial NCT04095390 · UNKNOWN

Trial details

NCT number
NCT04095390
Sponsor
Jinming Yu
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast CancerHER2-positive Breast Cancer
Start date
2019-09-30
Primary completion
2021-11-30
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.